Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Keravision(kera) -- Ignore unavailable to you. Want to Upgrade?

To: wily who wrote (288)	12/11/1999 7:11:00 AM
From: oilbabe	Read Replies (2) \| Respond to of 338

wily, Sure, there is a confluence of factors working against KERA here. Don't forget sellers from the secondary at $13, those who bought between $29 and $25 all got margined out, and VISX had bad news recently which, while not impacting KERA directly certainly didn't help the image of this sector. The market is looking for wireless, linux, e-tailers, etc. and could care less about correcting vision right now. There has also been a lot of tax loss selling because there has been a lot of money made the past few months, and not everyone is holding their hot stocks for "the long term". I have no doubt that KERA, at these levels, will provide a profitable return, even if it is only as a buyout!